Oral candidosis;Orale candidose

JDDG - Journal of the German Society of Dermatology

Volumn 6, Issue 7, 2008, Pages 593-597

  Reinel, Dieter ^a   Plettenberg, Andreas ^a   Seebacher, Claus ^a   Abeck, Dietrich ^a   Brasch, Jochen ^a   Cornely, Oliver ^a   Effendy, Isaak ^a   Ginter Hanselmayer, Gabriele ^a   Haake, Norbert ^a   Hamm, Gudrun ^a   Hipler, Uta Christina ^a   Hof, Herbert ^a   Korting, Hans Christian ^a   Mayser, Peter ^a   Ruhnke, Markus ^a   Schlacke, Kurt Heiner ^a   Tietz, Hans Jürgen ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CHLORHEXIDINE; CYTOSTATIC AGENT; FLUCONAZOLE; GLUCOCORTICOID; HEXETIDINE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; MICONAZOLE; NATAMYCIN; NYSTATIN; OCTENIDINE; OCTENIDOL; OCTENISEPT; PLACEBO; POSACONAZOLE; VORICONAZOLE;

CANDIDA; CLINICAL FEATURE; CLINICAL TRIAL; HUMAN; LABORATORY DIAGNOSIS; MOUTH MUCOSA; OROPHARYNX CANDIDIASIS; REVIEW; THRUSH;

ADMINISTRATION, ORAL; ADMINISTRATION, TOPICAL; ADULT; ANTIFUNGAL AGENTS; CANDIDIASIS, ORAL; CHILD; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; INFANT; INFANT, NEWBORN; MICROBIOLOGICAL TECHNIQUES; OPPORTUNISTIC INFECTIONS;

EID: 45749135842     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06801.x     Document Type: Review

References (26)

1. Arathoon EG, Gotuzzo E, Noriega LM et al. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiasis. Antimicrob Agenta Chemother 2002; 46: 451-457.
2. Bernhard H, Knoke M Diagnostik und Therapie der Endomykosen. Z Ges Inn Med 1980; 35: 522-529.
3. Blaschke-Hellmessen R, Schwarze R Amphotericin B-Spiegel in Faeces und Serum whrend oraler Verabreichung bei Risikoneugeborenen. Mycoses 1994; 37 (Suppl 1): 84-88.
4. Blomgren J, Berggren U, Jontell M Fluconazole versus nystatin in the treatment of oral candidosis. Act Odontol Scand 1998; 56: 202-205.
5. Butz-Jrgensen E, Holmstrup P, Krogh P Fluconazole in the treatment of Candida-associated denture stomatitis. Antimicrob Agents Chemother 1988; 32: 1859-1863
6. Bürger L, Heite HJ Nystatin-Nachweis im menschlichen Serum auf Grund fungistatischer Wirkungen. Klin Wschr 1961; 31: 1146.
7. Cross LJ, Bagg J, Wray D, Aitchison T A comparison of fluconazole and itraconazole in the management of denture stomatitis: a pilot study. J dentistry 1998; 26: 657-664
8. Dupont B, Drouhet E Fluconazole in the management of oropharyngeal candidosis in a predominantly HIV antibody-positive group of patients. J Med Vet Mycology 1988; 26: 67-71.
9. Groll AH, Just-Nübling G, Kurz M, Müller C, Nowak-Goettl U Schwabe D, Shah PM, Kornhuber B Fluconazole versus nystatin in the prevention of Candida infections in children and adolescents undergoing remission induction or consolidation chemotherapy for cancer. J Antimicrob Chemother 1997; 40: 855-862.
10. Haase G, Borg-von Zepelin M, Bernhardt H, Fegeler W, Harmsen D, Kappe R, Korting H C, Kuijpers A, Rüchel R, Schaller M, Schmalreck A, Seebacher C, Tintelnot K Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. Pilzinfektionen Teil I (MiQ 14), Teil II (MiQ 15). München Jena Urban & Fischer 2001.
11. Hatakka K, Ahola AJ, Yli-Knuuttila H, Richardson M, Poussa T, Meurman JH, Korpela R. Probiotics reduce the prevalence of oral candida in the elderly - a randomized controlled trial. J Dent Res 2007; 86: 125-30.
12. Hoegl L, Thoma-Greber E, Rcken M, Korting HC Shift from persistent oral pseudomembranous to erythematous candidosis in a human immunodeficiency virus(HIV)-infected patient upon combination treatment with an HIV protease inhibitor. Mycoses 1998; 41: 213-217.
13. King GN, Healy CM, Glover MT, Kwan JTC, Williams DM, Leigh IM, Thornbill MH Prevalence and risk factors associated with leukoplakia, hairy leukoplakia, erythematous candidiasis and gingival hyperplasia in renal transplant recipients. Oral Surg Oral Med Oral Pathol 1994;78: 718-26.
14. Koray M, Ak G, Kurklu E, Issever H, Tanyeri H, Kulekci G, Guc U Fluconazole and/or hexetidine for management of oral candidiasis associated with denture-induced stomatitis. Oral Diseases 2005; 11:309-313.
15. Kuriyama T, Williams DW, Bagg J, Coulter WA, Ready D, Lewis MA. In vitro susceptibility of oral Candida to seven antifungal agents. Oral Microbiol Immunol 2005; 20: 349-53.
16. Martin-Mazuelos E, Aller AI, Romero MJ, Rodriguez ArmijoA, Gutierrez MJ, Bernal S, Montero O Response to fluconazole and itraconazole of Candida spp. in denture stomatitis. Mycoses 1997; 40: 283-289.
17. Meunier F, Gerain J, Snoeck R, Libotte F, Lambert C, Ceuppens AM Fluconazole therapy of oropharyngeal candidosis in cancer patients. In: Fromtlind RA (Ed) Recent Trends in the Discovery, Development and Evaluation of Antifungal Agents. JR Prous Science Publishers, S.A.S 1987; S. 169-174.
18. Phillips P, De Beule K, Frechette G Tchamouroff S Vandercam B, Weitner L, Hoepeman A, Stingl G, Clotet B A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS. Clin Infect Dis 1998; 26: 1368-1373.
19. Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP, Fothergill AW, Redding SW, Rinaldi MG, Hilsenbeck SG, Patterson TF A randomized trial of continuous or intermittent therapy with fluconazole for oropharyngeal candidiasis in HIV-infected patients: Clinical outcomes and development of fluconazole resistance. Am J Med 1998; 105: 7-11.
20. Ruhnke M. Pilzinfektionen bei immunsupprimierten Patienten. Bremen, UNI-MED 2003 Seite 54.
21. Schwarze R, Blaschke-Hellmessen R, Graubner UB, Hoppe JE, Nenoff P, Roos R, Seebacher C Candidose. In: Scholz H, Belohradsky BH, Heininger U, Kreth W, Roos R (Hrsg.) Handbuch Infektionen bei Kindern und Jugendlichen. München, Futuramed 2000, S 195-206.
22. Skiest DJ, Vazquez JA, Anstead GM, Graybill JR, Reynes J, Ward D, Hare R, Boparai N, Isaacs R. Posaconazole for the treatment of azole-refractory oropharyngeal and esophageal candidiasis in subjects with HIV infection.Clin Infect Dis 2007; 44: 607-614.
23. Vazquez JA, Skiest DJ, Nieto L, Northland R, Sanne I, Gogate J, Greaves W, Isaacs R. A multicenter randomized trial evaluating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186.
24. Vazquez JA, Skiest DJ, Tissot-Dupont H, Lennox JL, Boparai N, Isaacs R. Safety and efficacy of posaconazole in the long-term treatment of azole-refractory oropharyngeal and esophageal candidiasis in patients with HIV infection. HIV Clin Trials 2007; 8:86-97.
25. Vazquez JA. Posaconazole for the management of mucosal candidiasis. Future Microbiol 2007; 2: 245-56.
26. Villanueva A, Arathoon EG, Gotuzzo E, Bermann RS, DiNubile MJ, Sable CA A randomized double-blind study of caspofungin versus amphotericin for treatment of candida esophagitis. Clin Infect Dis 2002;33: 1529-1535.